Interest of Impedancemetry in Monitoring Hydration and Hyponatremia During Subarachnoid Hemorrhages
Condition(s) studied
Investigational drug(s) / intervention(s)
Impedancemetry evaluation: Each patient eligible for the study will, additionally to the standard care, have repeated measure of impedancemetry along their hospital stay ; Theses measure will be compared to the usual measure of hydration and natremia and agreement between clinical status of interest will be discussed.
Study summary
Subarachnoid hemorrhage (SAH) is a rare and serious form of stroke, mainly linked to the rupture of an intracranial aneurysm responsible for bleeding into the meningeal spaces.
The main late serious complication is delayed cerebral ischemia (DCI), resulting in the appearance of new neurological deficits.
Prevention of ICR involves in particular maintaining euvolemia, and early treatment of hyponatremia, itself dependent on the level of volume.
Evaluation of water status and sodium balance is therefore essential. This assessment is complicated and relies on indirect parameters, both clinical and biological.
Impedancemetry, making it possible to measure water volumes and sodium load, could be an aid in the management of blood volume and sodium intake.
Eligibility
Primary outcome measure(s)
- Hydration measurements — Every 48 hours during the mean 21 days of stay in the neurological ICU.
The level of hydration is quantified by the indicator "Hydration of non-fat mass in%" using the impedancemetry. Threshold values for hydration indices are specific to the measurement performed on the patient and depend on their age, gender and body composition data.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hospices Civils de Lyon. Neurological ICU | Lyon | France | Recruiting |
More Hospices Civils de Lyon trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06646484 on ClinicalTrials.gov ↗ ← All trials in France